Pharmaqo UK GW501516 (Cardarine): Educational Guide to GW501516, Research Status, Risks, and Safety

Pharmaqo UK GW501516 (Cardarine) is a product name associated with GW501516, also known as GW1516, GSK-516, or Cardarine. The FDA Substance Registration System lists GW-501516 and Cardarine as names associated with the same chemical substance.

GW501516 is a research compound that has been investigated for its effects on metabolic pathways and energy metabolism. It is not an approved medicine for human use, and research was discontinued after serious concerns emerged from animal studies. The World Anti-Doping Agency and anti-doping authorities prohibit the substance in sport.

What Is Pharmaqo UK GW501516 (Cardarine)?

Pharmaqo UK GW501516 (Cardarine) is a product name associated with the research compound GW501516.

The compound is also known as:

• GW501516
• GW1516
• GSK-516
• Cardarine
• Endurobol

The FDA identifies GW-501516 as a chemical substance and lists Cardarine among its synonyms. However, the presence of a product name or label does not confirm the identity, purity, potency, or authenticity of any specific commercial product.

What Is GW501516?

GW501516 is a synthetic research compound that has been studied as a metabolic modulator. It is associated with activation of the peroxisome proliferator-activated receptor delta (PPARδ) pathway.

Early research investigated whether the compound could influence:

• Energy metabolism
• Fatty-acid metabolism
• Lipid levels
• Glucose metabolism
• Exercise-related metabolic pathways

Although early research generated interest in the compound, it was never approved as a human medicine.

Research and Development History

GW501516 was investigated as a potential treatment for metabolic and cardiovascular conditions.

However, research and development were discontinued after animal studies raised serious safety concerns. The World Anti-Doping Agency has warned athletes about GW501516 and stated that the compound was withdrawn from development after serious toxicities were identified in preclinical research.

The existence of early research does not mean that GW501516 is safe, effective, or approved for human use.

Cancer-Related Safety Concerns

One of the major safety concerns associated with GW501516 comes from animal research in which treatment was associated with the development of tumors in multiple organs.

Because of these findings, the compound was not developed into an approved human medicine. The long-term cancer risk in humans has not been adequately established, which is an important reason that using unapproved GW501516 products carries significant uncertainty.

It is not scientifically appropriate to claim that GW501516 is safe for humans simply because some individuals report using it without immediate symptoms.

Human Safety Data Are Limited

A major concern with GW501516 is the lack of adequate long-term human safety data.

Important unanswered questions include:

• Long-term cancer risk
• Long-term cardiovascular effects
• Effects on the liver
• Effects on metabolic health
• Potential interactions with other medicines
• Individual differences in susceptibility

Limited research cannot establish that a compound is safe for long-term human use.

Product Authenticity and Quality

A product labeled Pharmaqo UK GW501516 (Cardarine) may not necessarily contain genuine GW501516 or the stated concentration.

Products from uncertain or unregulated supply chains may involve risks such as:

• Incorrect active ingredient
• Incorrect concentration
• Undeclared substances
• Counterfeit packaging
• Contamination
• Inconsistent manufacturing quality

The appearance of tablets, capsules, liquids, or packaging cannot independently confirm identity, purity, potency, or safety.

The FDA has also taken regulatory action against sellers marketing GW501516 and other unapproved products for human use, emphasizing that unapproved new drugs cannot be legally marketed as approved treatments without appropriate authorization.

Is Cardarine a SARM?

Despite sometimes being marketed alongside SARMs, GW501516 is not a selective androgen receptor modulator.

It is associated with the PPARδ pathway and is generally classified as a metabolic modulator rather than an anabolic steroid or SARM.

This distinction is important because the compound has a different pharmacological mechanism from androgen-receptor drugs.

Effects on Metabolism

Research into GW501516 focused partly on metabolic pathways involving energy use and fatty-acid metabolism.

However, laboratory or animal findings cannot automatically be translated into proven human health benefits.

There is no approved clinical indication that allows GW501516 to be recommended as a treatment for:

• Weight loss
• Athletic endurance
• Diabetes
• High cholesterol
• Cardiovascular disease

Using a research compound outside a regulated clinical setting carries substantial uncertainty.

Athletic and Performance-Enhancement Concerns

GW501516 has attracted attention because of claims involving endurance and exercise performance.

However, it is prohibited in competitive sport.

Sport Integrity Australia identifies GW1516/GW501516 as a prohibited metabolic modulator and states that it is prohibited at all times under the applicable anti-doping framework.

Athletes subject to drug testing should consult the current anti-doping rules applicable to their sport.

Potential Health Risks

Because long-term human safety data are limited, the complete risk profile of GW501516 remains uncertain.

Potential concerns include:

• Cancer-related safety concerns based on animal findings
• Unknown long-term metabolic effects
• Possible cardiovascular effects
• Potential liver-related concerns
• Unknown drug interactions
• Product contamination
• Mislabeling or incorrect strength

A lack of immediate symptoms does not prove that a substance is safe.

Why Research Compounds Require Caution

Research compounds are often sold online with claims that may exceed the available scientific evidence.

A product marketed as:

• “Research use only”
• “Laboratory grade”
• “Performance enhancer”
• “Fat burner”
• “Endurance compound”

may still be intended for human consumption by the way it is advertised, despite disclaimers.

Consumers should be cautious when a product is not approved for human use and lacks reliable quality-control documentation.

Anti-Doping Status

GW501516 is prohibited in sport.

Anti-doping authorities identify the compound under metabolic modulators and prohibit it at all times.

A positive test can result in serious sporting consequences, including disqualification or sanctions.

Legal and Regulatory Considerations

The regulatory status of GW501516 varies between countries, but it is not an approved human medicine.

The availability of a product online does not mean that it is:

• Approved for human use
• Manufactured under pharmaceutical standards
• Legally authorized for sale
• Proven safe
• Accurately labeled

Regulations may apply to manufacture, sale, importation, distribution, and possession.

Frequently Asked Questions

What is Pharmaqo UK GW501516 (Cardarine)?

It is a product name associated with GW501516, a research compound also known as Cardarine or GW1516.

Is Cardarine a SARM?

No. GW501516 is generally associated with PPARδ activation and is not a SARM.

Is GW501516 approved for human use?

No. GW501516 was not developed into an approved human medicine.

Why was research into GW501516 discontinued?

Research was discontinued after serious safety concerns emerged from animal studies, including tumor development.

Is Cardarine prohibited in sport?

Yes. GW501516/GW1516 is prohibited under anti-doping regulations.

Can packaging confirm that a Cardarine product is genuine?

No. Packaging alone cannot confirm identity, purity, potency, or safety.

Is there a proven safe human dose?

There is no established approved human dosage for Cardarine because it is not an approved medicine for human use.

Final Educational Summary

Pharmaqo UK GW501516 (Cardarine) is a product name associated with the research compound GW501516, also known as GW1516, GSK-516, and Cardarine.

GW501516 was investigated for possible effects on metabolic pathways but was not developed into an approved human medicine. Research was discontinued after serious safety concerns emerged from animal studies, including tumor development. Long-term human safety remains uncertain.

GW501516 is also prohibited in competitive sport under anti-doping rules.

The identity, concentration, purity, authenticity, and manufacturing quality of any specific product marketed under the Pharmaqo UK name should not be assumed solely from its packaging.

Educational disclaimer: This article is provided for general educational and SEO purposes only. It does not confirm the composition of any specific product, endorse the use of unapproved research compounds, or provide dosing, cycling, stacking, or performance-enhancement instructions.